Daniel Loeb
Third Point
Daniel Loeb Valeant Pharmaceuticals International Inc stake
total: 588
Third Point VRX trades
- Total transactions:
- 2
- New positions:
- 1
- Sold out:
- 1
- Held since:
- 2014 Q1
- Held for:
- 1 quarter
- Latest activity:
- 2014 Q2
According to 2026 Q2 report, Daniel Loeb doesn't hold any Valeant Pharmaceuticals International Inc (VRX) shares. To date, the estimated cost basis is nearly $131.83 for "buy" trades and estimated average "sell" price is $131.83. Third Point first purchased VRX in 2014 Q1, initially acquiring 250,000 shares. Since the initial investment in Valeant Pharmaceuticals International Inc (VRX), Third Point has made 1 more transaction.
When did Daniel Loeb sell Valeant Pharmaceuticals International Inc (VRX)?
Daniel Loeb sold off the entire Valeant Pharmaceuticals International Inc (VRX) position in 2014 Q2.
When did Daniel Loeb buy Valeant Pharmaceuticals International Inc (VRX)?
Daniel Loeb first invested in Valeant Pharmaceuticals International Inc (VRX) in 2014 Q1 at the reported quarter-end price of $131.83 per share.
What's the cost basis of Third Point's VRX stake?
The estimated cost basis for Valeant Pharmaceuticals International Inc (VRX) stake is around $131.83 per share. This represents their average reported price* across all buy transactions
Estimated cost basis*
- Weighted AVG buy price:
- $131.83
- Weighted AVG sell price:
- $131.83
Daniel Loeb's historical trades in Valeant Pharmaceuticals International Inc
* Shares, change to shares, sold shares, shares held after: split-adjusted.
* Reported price: this doesn't represent the actual buy or sell price. It is the split-adjusted price of the security as of the last day of the reported period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
If the security is completely sold out, we show the reported split-adjusted price prior to the actual period.
* Estimated cost basis: based on "Reported price*" (not earlier than 2013 Q2). Calculation starts from the latest "new buy" activity to the latest "close out" activity (if any).
* Value or Price: If the security is completely sold out, we show the reported value (or price) prior to the actual period.
* New buy or own: this means there is no earlier reporting (for us or in general). So we can't know if the actual purchase of the security happened at the reported period or earlier.